April 29, 2015 | Nicholas Schork, the J. Craig Venter Institute's director of human biology, argues for an industry-wide pivot to clinical trial designs that can adapt to patients' unique profiles and drug responses — whether through basket or umbrella trials, or by rethinking routine compassionate use and off-label therapy cases to be more readily aggregated across care centers. Nature News